Biote Corp. (BTMD)
NASDAQHealth CareMedical - Care FacilitiesSnapshot 2026-09-04
$1.550.00%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - Care FacilitiesSnapshot 2026-09-04
QuarterlyIQ Insights · BTMD
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -80.5% |
| Our one-year growth estimate | diamond | 1.7% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 82.2 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 27 industry peers · Company calendar date is not available
BTMD — CEO transition
Dated 2026-06-17
Interim Chief Executive Officer — Mr. Peterson: Mr. Peterson was appointed as Interim Chief Executive Officer with a new employment agreement.
Why it matters: If revenue growth speeds up, it could signal a positive shift for the company. This would be important as the healthcare sector is maturing and slowing down.
Supportive ifBiote Corp. reports revenue growth above 10% year over year in the next earnings report.
Worry ifRevenue growth remains below 10% year over year.
Why it matters: Changes in leadership can affect how well the company executes its plans. Stable leadership is key for success.
Watch forManagement gives a good update on Bob Peterson's work as Interim CEO.
Also watch forThere are concerns about how well leaders are doing or if there is more instability.
Why it matters: Positive revenue growth is crucial to meet the 2026 target of over $190 million.
Supportive ifQ2 revenue is up from last year. This ends the recent decline.
Worry ifQ2 revenue is down from last year. This shows ongoing challenges.
Why it matters: Hitting this target is key for financial health and investor trust. It shows efficiency and revenue growth.
Supportive ifAdjusted EBITDA for 2026 is more than $25 million.
Worry ifAdjusted EBITDA is under $25 million. This shows financial issues.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$358 on $10,000 · ±3.6% | How much price usually moves either way. |
| Bad day | $814 loss on $10,000 · 8.1% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $6,243 loss on $10,000 · 62.4% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Confirming revenue guidance is key for investor trust. It shows good management.
Supportive ifRevenue for 2026 exceeds $190 million as reported in Q3 earnings.
Worry ifRevenue is under $190 million. This means guidance was not met.
Why it matters: Growth in this area can help offset drops in procedure revenue. It supports overall revenue.
Supportive ifDietary supplements revenue grows at a mid to high single-digit rate in 2026.
Worry ifDietary supplements will grow less than 5% in 2026.
Why it matters: Stable leadership is important for the company's plans. Changes could show confidence or worry.
Watch forA permanent CEO has been announced.
Also watch forThere is a long delay in naming a permanent CEO or more leadership changes.
Why it matters: Better procedure revenue is important for growth after a decline. Management thinks this shows recovery from recalls.
Supportive ifQ3 procedure revenue is up from Q2. It should be over $30.3 million.
Worry ifQ3 procedure revenue drops or stays below $30.3 million.